Modern classification, progression factors, treatment and outcomes of primary mesangial proliferative glomerulonephritis

Cover Page

Cite item


The choice of treatment of mesangial proliferative glomerulonephritis (post-infection, immunoglobulin A, G and M nephritis) is performed taking into account the remission achievement, slowing of progression and reduction of the risk of recurrences of glomerulonephritis. The efficiency of etiologic factor removing is debatable: glomerulonephritis associated with infections usually resolves after their elimination; individual patients achieve immunoglobulin A nephritis remission with persistent antimicrobial treatment of focal infection, but surgical removal of the focus (tonsillectomy) does not affect the long-term prognosis, therefore it is not recommended. Treatment of immunoglobulin A nephritis with oral prednisone for up to 4 months, sometimes in combination with cyclophosphamide (cyclophosphane), reduces the likelihood of its relapse. At low risk of progression of immunoglobulin A nephritis with proteinuria less than 1 g/day, long-term therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers is indicated with administration of maximum tolerated doses for proteinuria more than 1 g/day. Also fish oil 3 g/day is administered for up to 2 years. If proteinuria more than 1 g/day persists for 3-6 months, corticosteroids are recommended for 6 months. With mild renal dysfunction, corticosteroids are prescribed orally or in pulse-therapy with high doses intravenously and maintenance therapy with low doses orally. Immunosuppressive therapy - cyclophosphamide, cyclosporine, azathioprine, mycophenolate mofetil - in combination with corticosteroids is indicated in rapid loss of renal function or massive/moderate proteinuria. In minimal proteinuria immunosuppressive therapy is considered to be unreasonable. Use of intravenous immunoglobulin for immunoglobulin A nephritis from the point of view of lesser toxic effect is possible only as the induction therapy. Currently, there are no clinical recommendations for the treatment of immunoglobulin M nephritis, in case of nephrotic syndrome, corticosteroids are the drugs of the 1st line. There are isolated studies of the use of cyclophosphamide, mycophenolate mofetil, and cyclosporine, with the achievement of remission in frequent relapses of nephrotic syndrome or steroid drug resistance. The cases of immunoglobulin M nephritis treates with retuximab with a positive effect are described. The effectiveness of immunoglobulin G nephritis treatment is less studied, the choice of treatment is similar to that of immunoglobulin A and M nephritis.

About the authors

O N Sigitova

Kazan State Medical University

Author for correspondence.
Kazan, Russia

T Yu Kim

Kazan State Medical University

Kazan, Russia

R R Sharipova

Kazan State Medical University

Kazan, Russia


  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2013; 3 (1): 1-150.
  2. Бикбов Б.Т., Томилина Н.А. Состав больных и показатели качества лечения на заместительной терапии терминальной хронической почечной недостаточности в Российской Федерации в 1998-2013 гг. (Отчёт по данным регистра заместительной почечной терапии Российского диализного общества. Часть вторая.) Нефрол. и диализ. 2016; 18 (2): 98-164.
  3. Kawasaki Y. The pathogenesis and treatment of IgA nephropathy. Fukushima J. Med. Sci. 2008; 54 (2): 43-60. doi: 10.5387/fms.54.43.
  4. Дядык Л.И., Дикштейн Р.Л., Василенко И.В. и др. Клинико-лабораторная характеристика и эффективность глюкокортикоидной терапии больных первичным диффузным мезангиопролиферативным гломерулонефритом. Терап. арх. 1987; 59 (8): 35-37.
  5. Шулутко Б.И. Соотношение различных форм первичного гломерулонефрита в современных условиях и их диагностические критерии (опыт работы нефрологического отделения, клинико-морфологический анализ 3000 наблюдений). Терап. арх. 1992; 64 (6): 40-43.
  6. Ballardie F.W., Gartside Sand Mallick N.P. Computer prediction of the need for dialysis and transplantation using calculated creatinine clearance. NP Br. Med. J. (Clin. Res. Ed.) 1983; 286: 1328-1331. PMID: 6404450.
  7. Cameron J.S. Lupus nephritis. J. Am. Soc. Nephrol. 1999; 10 (2): 413-424. PMID: 10215343.
  8. Chan M.K., Chan K.W., Chan P.C. et al. Adult-onset mesangiocapillary glomerulonephritis: A disease with a poor prognosis. Q. J. Med. 1989; 72 (267): 599-607. PMID: 2608879.
  9. Aucouturier P., Monteiro R.C., Noel L.H. et al. Glomerular and serum immunoglobulin G subclasses in IgA nephropathy. Clin. Immunol. Immunopathol. 1989; 51: 338-347. doi: 10.1016/0090-1229(89)90032-9.
  10. Шилов Е.М., Смирнов А.В., Козловская Н.Л. Нефрология. Клинические рекомендации. М.: ГЭОТАР-Медиа. 2016; 816 с.
  11. Mubarak M., Naqvi R., Kazi J. et al. Immunoglobulin M nephropathy in adults: A clinicopathological study. Iran J. Kidney Dis. 2013; 7 (3): 214-219. PMID: 23689154.
  12. Schena F.P. Survey of the Italian registry of renal biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrol. Dial. Transplant. 1997; 12 (3): 418-426. doi: 10.1093/ndt/12.3.418.
  13. Jalalah S.M. IgG glomerulonephritis: a morphologic study of a rare entity. Saudi J. Kidney Dis. Transpl. 2009; 20 (5): 798-801.
  14. Sato M., Kojima H., Nabeshima K. et al. Primary glomerulonephritis with predominant mesangial immunoglobulin G deposits: A distinct entity? Nephron. 1993; 64 (1): 122-128. PMID: 8502317.
  15. Yoshikawa N., Iijima K., Shimomura M. et al. IgG-associated primary glomerulonephritis in children. Clin. Nephrol. 1994; 42 (5): 281-287. PMID: 7851027.
  16. Pinto S.W., Sesso R., Vasconcelos E. et al. Follow-up of patients with epidemic poststreptococcal glomerulonephritis. Am. J. Kidney Dis. 2001; 38 (2): 249-255. doi: 10.1053/ajkd.2001.26083.
  17. Berthoux F.C., Mohey H., Afiani A. Natural history of primary IgA nephropathy. Semin. Nephrol. 2008; 28 (1): 4-9. doi: 10.1016/j.semnephrol.2007.10.001.
  18. Шилов Е.М., Тареева И.Е., Иванов А.А. и др. Течение и прогноз мезангиопролиферативного гломерулонефрита. Терап. арх. 2002; 74 (6): 11-18.
  19. D’Amico G. Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. Am. J. Kidney Dis. 2000; 36 (2): 227-237. doi: 10.1053/ajkd.2000.8966.
  20. Szeto C.C., Lai F.M., To K.F. et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am. J. Med. 2001; 110 (6): 434-437. doi: 10.1016/S0002-9343(01)00659-3.
  21. Tamura S., Masuda Y., Inokuchi I. et al. Effect of and indication for tonsillectomy in IgA nephropathy. Acta Otolaryngol. 1993; 508: 23-28. doi: 10.3109/00016489309130262.
  22. Akagi H., Kosaka M., Hattori K. et al. Long-term results of tonsillectomy as a treatment for IgA nephropathy. Acta Otolaryngol. Suppl. 2004; 555: 38-42. PMID: 15768796.
  23. Feehally J., Coppo R., Troyanov S. et al. Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy. Nephron. 2016; 132 (1): 15-24. doi: 10.1159/000441852.
  24. Hotta O., Miyazaki M., Furuta T. et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am. J. Kidney Dis. 2001; 38 (4): 736-743. doi: 10.1053/ajkd.2001.27690.
  25. Hoshino Y., Kaga T., Abe Y. et al. Renal biopsy findings and clinical indicators of patients with hematuria without overt proteinuria. Clin. Exp. Nephrol. 2015; 19 (5): 918-924. doi: 10.1007/s10157-015-1090-6.
  26. Hoshino J., Fujii T., Usui J. et al. Renal outcome after tonsillectomy plus corticosteroid pulse therapy in patients with immunoglobulin A nephropathy: result of multicenter cohort study. Clin. Exp. Nephrol. 2016; 20 (4): 618-627. doi: 10.1007/s10157-015-1194-z.
  27. Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Intern. Suppl. 2012; 2: 139-274. doi: 10.1038/kisup.2012.9.
  28. Lai K.N., Li P.K., Lui S.F. et al. Membranous nephropathy related to hepatitis B virus in adults. N. Engl. J. Med. 1991; 324 (21): 1457-1463. doi: 10.1056/NEJM199105233242103.
  29. Картамышева Н.Н., Чумакова О.В., Кучеренко А.Г. и др. Прогрессирование хронического гломерулонефрита: клинико-морфологические взаимосвязи. Нефрол. и диализ. 2003; 5 (4): 395-398.
  30. Barbour S.J., Reich H.N. Risk stratification of patients with IgA nephropathy. Am. J. Kidney Dis. 2012; 59 (6): 865-873. doi: 10.1053/j.ajkd.2012.02.326.
  31. Franceschini N., Deng Y., Flessner M.F. et al. Smoking patters and chronic kidney disease in US Hispanics: Hispanic Community health Study/Study of Latinos. Nephrol. Dial. Transplant. 2016; 31 (10): 1670-1676. doi: 10.1093/ndt/gfw210.
  32. Caliskan Y., Ozluk Y., Celik D. et al. The clinical significance of uric acid and complement activation in the progression of IgA nephropathy. Kidney Blood Press Res. 2016; 41 (2): 148-157. doi: 10.1159/000443415.
  33. Куликова Е.В., Кухтевич А.В., Зилов В.Г. Конституциональная характеристика и течение хронического гломерулонефрита. Нефрол. и диализ. 2003; 5 (2): 148-152.
  34. O’Donoghue D.J., Lawler W., Hunt L.P. et al. IgM-associated primary diffuse mesangial proliferative glomerulonephritis: Natural history and prognostic indicators. Q. J. Med. 1991; 79 (288): 333-350. doi: 10.1093/oxfordjournals.qjmed.a068554.
  35. Sobarzo Toro M., Vilches A. Membranous kidney diseases in adults. Medicina (B. Aires). 2004; 64 (1): 59-65. PMID: 15034960.
  36. Шилов Е.М., Иванов A.A., Троепольская О.В., Краснова Т.Н. Течение и прогноз мезангиопролиферативного гломерулонефрита. Успехи нефрологии. Сб. науч. тр. М.: ММА им. Сеченова. 2001; 165-183.
  37. Shiiki H., Saito T., Nishitani Y. et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004; 65 (4): 1400-1407. doi: 10.1111/j.1523-1755.2004.00518.x.
  38. Maschio G., Cagnoli L., Claroni F. et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol. Dial. Transplant. 1994; 9 (3): 265-269. PMID: 8052432.
  39. Jo Y.I., Na H.Y., Moon J.Y. et al. Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial. Korean J. Intern. Med. 2016; 31 (2): 335-343. doi: 10.3904/kjim.2014.266.
  40. Beck L., Bomback A.S., Choi M.J. et al. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for glomerulonephritis. Am. J. Kidney Dis. 2013; 62 (3): 403-441. doi: 10.1053/j.ajkd.2013.06.002.
  41. Bartosik L.P., Lajoie G., Sugar L., Cattran D.C. Predicting progression in IgA nephropathy. Am. J. Kidney Dis. 2001; 38 (4): 728-735. doi: 10.1053/ajkd.2001.27689.
  42. Le W., Liang S., Hu Y. et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol. Dial. Transplant. 2012; 27 (4): 1479-1485. doi: 10.1093/ndt/gfr527.
  43. Gutierrez E., Zamora I., Ballarin J.A. et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J. Am. Soc. Nephrol. 2012; 23 (10): 1753-1760. doi: 10.1681/ASN.2012010063.
  44. Contreras G., Pardo V., Leclercq B. et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 2004; 350 (10): 971-980. doi: 10.1056/NEJMoa031855.
  45. Manno C., Torres D.D., Rossini M. et al. Randomized controlled clinical trial of corticosteroids plus ACE inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol. Dial. Transplant. 2009; 24 (12): 3694-3701. doi: 10.1093/ndt/gfp356.
  46. Tesar V., Troyanov S., Bellur S. et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J. Am. Soc. Nephrol. 2015; 26 (9): 2248-2258. doi: 10.1681/ASN.2014070697.
  47. Pozzi C., Andrulli S., Pani A. et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J. Am. Soc. Nephrol. 2010; 21 (10): 1783-1790. doi: 10.1681/ASN.2010010117.
  48. Rauen T., Eitner F., Fitzner C. et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N. Engl. J. Med. 2015; 373 (23): 2225-2236. doi: 10.1056/NEJMoa1415463.
  49. Lai K.N., Lai F.M., Li P.K. et al. Cyclosporin treatment of IgA nephropathy: A short term controlled trial. Br. Med. J. (Clin. Res. Ed.) 1987; 295: 1165-1168. doi: 10.1136/bmj.295.6607.1165.
  50. Austin H.A. 3rd, Klippel J.H., Balow J.E. et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. 1986; 314 (10): 614-619. doi: 10.1056/NEJM198603063141004.
  51. Ballardie F.W., Roberts I.S. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J. Am. Soc. Nephrol. 2002; 13: 142-148. PMID: 11752031.
  52. Haubitz M., Schellong S., Gobel U. et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 1998; 41 (10): 1835-1844. doi: 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q.
  53. Oshima S., Kawamura O. Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophosphamide therapy. Clin. Exp. Nephrol. 2008; 12 (4): 264-269. doi: 10.1007/s10157-008-0045-6.
  54. Pozzi C., Del Vecchio L., Locatelli F. Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review. G. Ital. Nefrol. 2002; 19 (5): 523-528. PMID: 12439840.
  55. Sugawara K., Takeda K., Nakai K. et al. Clinical evaluation of tonsillectomy with modified high-dose intravenous methylprednisolone therapy in patients with IgA nephropathy. Nihon Jinzo Gakkai Shi. 2008; 50 (8): 1017-1023. PMID: 19172803.
  56. Barratt J., Feehally J. Treatment of IgA nephropathy. Kidney Int. 2006; 69 (11): 1934-1938. doi: 10.1038/
  57. Schena F.P., Manno C. Intensive supportive care plus immunosuppression in IgA nephropathy. N. Engl. J. Med. 2016; 374 (10): 992. doi: 10.1056/NEJMc1600141#SA3.
  58. Rasche F.M., Keller F., von Muller L. et al. Sequential immunosuppressive therapy in progressive IgA nephropathy. Contrib. Nephrol. 2007; 157: 109-113. doi: 10.1159/0000102313.
  59. Rasche F.M., Keller F., Rasche W.G. et al. Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive IgA nephropathy: a long-term follow-up. Clin. Exp. Immunol. 2016; 183 (2): 307-316. doi: 10.1111/cei.12719.
  60. Schaier M., Scholl C., Scharpf D. et al. High interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitis. Nephrol. Dial. Transplant. 2015; 30 (1): 138-145. doi: 10.1093/ndt/gfv065.
  61. Liu X.W., Li D.M., Xu G.S. et al. Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. Int. J. Clin. Pharmacol. Ther. 2010; 48: 509-513. doi: 10.5414/CPP48509.
  62. Yaginuma T., Yamamoto H., Mitome J. et al. Successful treatment of nephrotic syndrome caused by recurrent IgA nephropathy with chronic active antibody-mediated rejection three years after kidney transplantation. Clin. Transplant. 2011; 25 (23): 28-33. doi: 10.1111/j.1399-0012.2011.01456.x.
  63. Bomback A.S., Canetta P.A., Beck L.H. et al. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am. J. Nephrol. 2012; 36 (1): 58-67. doi: 10.1159/000339287.
  64. Haas M. Histologic subclassification of IgA nephropathy: A clinicopathologic study of 244 cases. Am. J. Kidney Dis. 1997; 29 (6): 829-842. doi: 10.1016/S0272-6386(97)90456-X.
  65. Arias L.F., Prada M.C., Velez-Echeverri C. et al. IgM nephropathy in children: clinicopathologic analysis. Nefrologia. 2013; 33 (4): 532-538. doi: 10.3265/Nefrologia.pre2013.Mar.11962.
  66. Myllymaki J., Saha H., Mustonen J. et al. IgM nephropathy: clinical picture and long-term prognosis. Am. J. Kidney Dis. 2003; 41 (2): 343-350. doi: 10.1053/ajkd.2003.50042.
  67. Vanikar A. IgM nephropathy; can we still ignore it. J. Nephropathol. 2013; 2 (2): 98-103. doi: 10.12860/JNP.2013.16.
  68. Betjes M.G., Roodnat J.I. Resolution of IgM nephropathy after rituximab treatment. Am. J. Kidney Dis. 2009; 53 (6): 1059-1062. doi: 10.1053/j.ajkd.2008.10.038.
  69. Fakhouri F., Darre S., Droz D. et al. Mesangial IgG glomerulonephritis: A distinct type of primary glomerulonephritis. J. Am. Soc. Nephrol. 2002; 13 (2): 379-387. PMID: 11805165.

© 2017 Sigitova O.N., Kim T.Y., Sharipova R.R.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies